Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: kawanami d. Diabetes Obes Metab. 2024 Aug;26(8):3248-3260. doi: 10.1111/dom.15652. Epub 2024 May 19. Diabetes Obes Metab. 2024. PMID: 38764356
Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y, Toyokawa K, Oda N, Muta Y, Yokomizo H, Fukumoto S, Kawanami D. Takashi Y, et al. Among authors: kawanami d. Front Endocrinol (Lausanne). 2022 Dec 2;13:1004624. doi: 10.3389/fendo.2022.1004624. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36531500 Free PMC article.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. Kobayashi K, et al. Among authors: kawanami d. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231222837. doi: 10.1177/14791641231222837. Diab Vasc Dis Res. 2023. PMID: 38096503 Free PMC article.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: kawanami d. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, Shikata K; CANPIONE study Investigators. Miyamoto S, et al. Among authors: kawanami d. Kidney Int. 2024 Nov;106(5):972-984. doi: 10.1016/j.kint.2024.08.019. Epub 2024 Aug 30. Kidney Int. 2024. PMID: 39216659 Free article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Elevation in white blood cell count and development of hyper LDL cholesterolemia.
Okutsu S, Kato Y, Takeoka H, Funakoshi S, Maeda T, Yoshimura C, Kawazoe M, Satoh A, Tada K, Takahashi K, Ito K, Yasuno T, Fujii H, Mukoubara S, Saku K, Kodama S, Kawanami D, Masutani K, Arima H, Nabeshima S. Okutsu S, et al. Among authors: kawanami d. Sci Rep. 2023 May 22;13(1):8292. doi: 10.1038/s41598-023-35436-6. Sci Rep. 2023. PMID: 37217577 Free PMC article.
Serum triglyceride levels and incidence of hypertension in a general Japanese population: ISSA-CKD study.
Ishida S, Kondo S, Funakoshi S, Abe M, Satoh A, Kawazoe M, Maeda T, Yoshimura C, Nishida Y, Tada K, Takahashi K, Ito K, Yasuno T, Kawanami D, Miura SI, Kodama S, Saku K, Mukobara S, Masutani K, Arima H. Ishida S, et al. Among authors: kawanami d. Hypertens Res. 2023 May;46(5):1122-1131. doi: 10.1038/s41440-023-01175-4. Epub 2023 Jan 24. Hypertens Res. 2023. PMID: 36690809
Association between serum ALT levels and incidence of new-onset diabetes in general population of Japanese: a longitudinal observational study (ISSA-CKD).
Morinaga A, Iwanaga K, Maki K, Ueno T, Kawano K, Funakoshi S, Yamanokuchi T, Tsuji M, Abe M, Satoh A, Kawazoe M, Maeda T, Yoshimura C, Takahashi K, Tada K, Ito K, Yasuno T, Kawanami D, Masutani K, Arima H. Morinaga A, et al. Among authors: kawanami d. BMJ Open. 2023 Aug 7;13(8):e074007. doi: 10.1136/bmjopen-2023-074007. BMJ Open. 2023. PMID: 37550028 Free PMC article.
84 results